Immune Defense Protein Impact On Respiratory Immune Outcomes
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Quantec Ltd
- Study ID
- NCT07431840
- Status
- Recruiting
Conditions
- Influenza
- Upper Respiratory Disease
- Viral Upper Respiratory Infection
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Immune Defense Protein 50mg Dose — DIETARY_SUPPLEMENTIDP dose of 50mg
- IDP 200mg Dose — DIETARY_SUPPLEMENTIDP dose of 200mg
- Matching Placebo — DIETARY_SUPPLEMENTMatching Placebo
Study Details
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Key Dates
- Start date
- Dec 5, 2025
- Status verified
- Feb 2026
- Primary completion
- May 19, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Group 1: Study Product 50mg Dose50mg of Study Product
- Experimental: Group 2: Study Product 200mg Dose200mg of Study Product
- Placebo Comparator: Group 3: Matching PlaceboParticipants will receive Matching Placebo
Primary Outcome Measure
Impact on Upper Respiratory Symptom Incidence, Duration and Severity [ Time Frame: 17 weeks ]
Central Contacts
- Noah Craft, M.D., Ph.D213-328-0919
- Azure Grant
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| People Science, Inc. | Los Angeles | California | 90045 | Azure Grant |
Find similar trials in Los Angeles, CA
By research site
Related Studies
- High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) RecipientsPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Stanford, California
- The Effects of Endotracheal Suctioning on Pain and Serum MarkersRecruiting · Loma Linda University · Loma Linda, California
- A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of InfluenzaPHASE3 · Recruiting · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Anniston, Alabama
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsPHASE3 · Recruiting · ModernaTX, Inc. · San Bernardino, California